BACE1 and early-onset autosomal dominant Alzheimer disease: Progressin this field will continue to rely on integrated approaches thatunite synthetic chemistry, structural insights, and pharmacologicalevaluation to unlock the therapeutic potential of BACE-1 inhibitionin Alzheimer’s disease.